J
Jazz Pharmaceuticals Jazzz.O said on Tuesday that it had agreed to a $ 145 million settlement to solve a series of anti -monopoly claims related to the drug, Xyrem.
Xyrem, a certified drug in the United States, is used to treat excessive drowsiness during the day and a sudden loss of muscle control in patients suffering from scourge, which is a chronic neurological disorder.
Jazz Pharma lawsuits were accused of coordinating a scheme to delay the publication of a general version of Xyrem, which was made by Hikma Pharmaceuticals HIK.L, leading to inflated prices for health plans.
Prosecutors, who include the city of Proventins, Rod Island, and the Hospital Fund at the New York State Council for Health and Hospitals, presented cases accusing jazz of violating American monopoly laws.
Jazz is accused of conducting a cash boost that has been a competitor’s competitor for years for years, and Xyre’s distribution exclusively through one specialized pharmacy.
Despite the approval of the settlement, jazz denied any allegations of misconduct.
The Ireland -based company said that it plans to use its current cash reserves to finance the settlement and expects to record pre -tax fees of 145 million dollars in the first quarter of 2025 regarding the settlement.
The company reported sales of $ 233.8 million from Xyrem in 2024.
Hikma did not immediately respond to a Reuters request for comment.
(Participated in the reports of Kamal Chaudhry in Bangaluru; Al -Tahrir by Muhammad Safi Shamsi)
Was this article valuable?
Here are more articles you may enjoy.
Interested in Drugs?
Get automatic alerts for this topic.
